Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Preventing clinically important deterioration with single-inhaler triple therapy in COPD.

Naya I, Compton C, Ismaila AS, Birk R, Brealey N, Tabberer M, Zhu CQ, Lipson DA, Criner G.

ERJ Open Res. 2018 Oct 3;4(4). pii: 00047-2018. doi: 10.1183/23120541.00047-2018. eCollection 2018 Oct.

2.

Hair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPD.

Hassall D, Brealey N, Wright W, Hughes S, West A, Ravindranath R, Warren F, Daley-Yates P.

Pulm Pharmacol Ther. 2018 Aug;51:59-64. doi: 10.1016/j.pupt.2018.07.001. Epub 2018 Jul 4.

3.

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.

Mehta R, Pefani E, Beerahee M, Brealey N, Barnacle H, Birk R, Zhu CQ, Lipson DA.

J Clin Pharmacol. 2018 Nov;58(11):1461-1467. doi: 10.1002/jcph.1253. Epub 2018 May 15.

4.

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.

Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA.

ERJ Open Res. 2018 May 4;4(2). pii: 00119-2017. doi: 10.1183/23120541.00119-2017. eCollection 2018 Apr.

5.

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators.

N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.

6.
7.

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.

8.

Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 May 1;197(9):1230-1231. doi: 10.1164/rccm.201711-2313LE. No abstract available.

PMID:
29241016
9.

Reply to Suissa and Ariel: The FULFIL Trial.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):542-543. doi: 10.1164/rccm.201709-1831LE. No abstract available.

PMID:
28950068
10.

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.

Ismaila AS, Birk R, Shah D, Zhang S, Brealey N, Risebrough NA, Tabberer M, Zhu CQ, Lipson DA.

Adv Ther. 2017 Sep;34(9):2163-2172. doi: 10.1007/s12325-017-0604-x. Epub 2017 Sep 5.

11.

Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease".

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1083-1084. doi: 10.1164/rccm.201704-0818LE. No abstract available.

PMID:
28534669
12.

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.

PMID:
28375647
13.

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.

Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N.

Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.

14.

Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer.

Mehta R, Montembault M, Warren F, Gupta A, Brealey N, Moore A.

J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):386-92. doi: 10.1089/jamp.2015.1236. Epub 2016 Jan 29.

PMID:
26824933
15.

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Prime D, de Backer W, Hamilton M, Cahn A, Preece A, Kelleher D, Baines A, Moore A, Brealey N, Moynihan J.

J Aerosol Med Pulm Drug Deliv. 2015 Dec;28(6):486-97. doi: 10.1089/jamp.2015.1224. Epub 2015 Sep 15.

16.

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.

Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A.

Int J Clin Pharmacol Ther. 2015 Sep;53(9):753-64. doi: 10.5414/CP202390. Erratum in: Int J Clin Pharmacol Ther. 2016 Jan;54(1):76-80. Int J Clin Pharmacol Ther. 2016 Jan;54(1):76-80.

17.

Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.

Mehta R, Hardes K, Brealey N, Tombs L, Preece A, Kelleher D.

Int J Chron Obstruct Pulmon Dis. 2014 Dec 18;10:15-23. doi: 10.2147/COPD.S68094. eCollection 2015.

18.

A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.

Pulm Pharmacol Ther. 2014 Oct;29(1):49-57. doi: 10.1016/j.pupt.2014.07.002. Epub 2014 Jul 12.

PMID:
25020273
19.

Supplemental Content

Loading ...
Support Center